Abstract
In this study, 600mg/day or 1200mg/day of Clinofibrate (Lipoclin®) was orally administered to 42 hyperlipidemic patients during three months. Clinofibrate decreased serum triglyceride about 32% by 600mg/day and 48% by 1200mg/day. It decreased serum cholesterol 5% by 600mg/day and 7% by 1200mg/day. Those patients were classified to 28 Type IIb, 9 Type ha and 5 Type IV hyperlipidemics according to the WHO pheno-types' classification of hyperlipidemia. The lipid lowering effects in each lipoprotein fraction were studied. The lipoproteins were fractionated by ultracentrifugation using Beckman Lp-42 Ti rotor. In Type IIb hyperlipidemics, 600mg/day of Clinofibrate lowered VLDL and LDL cholesterol and VLDL triglyceride and increased HDL cholesterol. However, 1200mg/day of Clinofibrate lowered VLDL cholesterol and triglyceride but increased LDL cholesterol, slightly. Clinofibrate was known to increase lipoprotein lipase activity in peripheral adipose tissue. So, this difference between 600mg/day and 1200mg/day might be due to that of the amount of VLDL catabolized by lipoprotein lipase. The clinical usefulness of 1200mg/day administration of Clinofibrate was partly confirmed but must be further studied in the cases of longer trial by more precise observation of lipoprotein metabolism. No adverse reaction was observed in this trial.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
